FDA warns sellers of unapproved versions of Novo's and Lilly's obesity drugs
Two companies in the US have been targeted by the FDA after selling unapproved online versions of obesity and diabetes drugs from Novo Nordisk and Eli Lilly, writes industry media FiercePharma.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.